NLM Digital Collections

Search

Start Over Subjects Diabetes Mellitus, Type 2 -- drug therapy ✖Remove constraint Subjects: Diabetes Mellitus, Type 2 -- drug therapy Publication Year 2000 to 2024 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2024">2024</span>

1. Controversies in the management of patients with type 2 diabetes: final report

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 2014
Subject(s):
Comparative Effectiveness Research
Diabetes Mellitus, Type 2 -- drug therapy
Disease Management
Blood Glucose -- analysis
Blood Glucose -- metabolism
Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
Drug Therapy, Combination
Hemoglobin A, Glycosylated -- analysis
Hypoglycemic Agents -- administration & dosage
Hypoglycemic Agents -- therapeutic use
Insulin -- therapeutic use
Metformin -- administration & dosage
Metformin -- therapeutic use
Monitoring, Ambulatory
Randomized Controlled Trials as Topic
Receptors, Glucagon -- agonists
Sulfonylurea Compounds -- administration & dosage
Sulfonylurea Compounds -- therapeutic use
Treatment Outcome
Humans
New England
United States

2. Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):
Blood Glucose -- drug effects
Diabetes Mellitus, Type 1 -- drug therapy
Diabetes Mellitus, Type 2 -- drug therapy
Hypoglycemia -- prevention & control
Hypoglycemic Agents -- therapeutic use
Insulin, Long-Acting -- administration & dosage
Insulin, Long-Acting -- therapeutic use
Blood Glucose -- metabolism
Cost-Benefit Analysis
Diabetes Mellitus, Type 1 -- blood
Diabetes Mellitus, Type 1 -- complications
Diabetes Mellitus, Type 2 -- blood
Diabetes Mellitus, Type 2 -- complications
Hypoglycemia -- blood
Hypoglycemia -- chemically induced
Hypoglycemic Agents -- administration & dosage
Insulin -- adverse effects
Severity of Illness Index
Humans
United States

3. Tirzepatide for type 2 diabetes: final report

Author(s):
Lin, Grace A., author
Nikitin, Dmitriy, author
Moradi, Ashton, author
Herron-Smith, Serina, author
Pearson, Steven D., author
Campbell, Jon D., author
Brouwer, Elizabeth, author
Chen, Yilin, MPH, author
Hansen, Ryan N., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 15, 2022
Subject(s):
Diabetes Mellitus, Type 2 -- drug therapy
Gastric Inhibitory Polypeptide -- therapeutic use
Hypoglycemic Agents -- therapeutic use
Incretins -- therapeutic use
United States

5. Feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with Type 2 Diabetes Mellitus: guidance for industry and Food and Drug Administration staff

Publication:
[Silver Spring, MD] : Center for Devices and Radiological Health, May 6, 2022
Subject(s):
Clinical Studies as Topic
Diabetes Mellitus, Type 2 -- drug therapy
Glycemic Control
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration